New Zealand markets close in 6 hours 5 minutes

Koninklijke Philips N.V. (PHG)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
21.69+1.06 (+5.14%)
At close: 04:00PM EDT
21.69 -0.01 (-0.05%)
After hours: 04:02PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Philips awarded top honor by Red Dot jury with Design Team of the Year award

    Philips Ingenia MR Philips Lumify portable ultrasound Philips Chief Design Officer Sean Carney receives the Red Dot Design Team of the Year 2022 award June 21, 2022 Prestigious title awarded for the team’s multi-disciplinary and human-centered approach to designing solutions that improve people’s livesCelebratory event accompanied by presentation of awards for Philips’ three Red Dot Design ‘Best of the Best’ product ratings Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a glo

  • GlobeNewswire

    Philips to repurchase up to 3.2 million shares to cover long-term incentive and employee stock purchase plans

    June 13, 2022 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 3.2 million shares to cover certain of its obligations arising from its long-term incentive and employee stock purchase plans. At the current share price, the shares represent an amount of up to approximately EUR 68 million. The repurchases will be executed through one or more individual forward transactions, expected to be entered into in the second and/or the third quar

  • GlobeNewswire

    Philips announces positive three-year clinical research results from its Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial

    Philips Tack Endovascular System (4F) - 1 Philips Tack Endovascular System (4F) - 2 June 13, 2022 For below-the-knee arterial dissection repair following balloon angioplasty, innovative medical technology shows sustained treatment effect and positive impact on quality of life for patients with critical limb ischemia (CLI)First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage (93.9%) and freedom from clinically-driven target lesion revasculariza